New tracer could reveal hidden immune activity in brain diseases
NCT ID NCT05849467
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests whether a radioactive tracer called 89Zr-Df-crefmirlimab can help PET scans detect certain immune cells (CD8+ T cells) in the brain and spinal cord of people with multiple sclerosis (MS) or progressive multifocal leukoencephalopathy (PML). About 15 adults will receive the tracer and undergo PET and MRI scans over several weeks. The goal is to better understand how these diseases affect the central nervous system.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
89Zr-Df-crefmirlimab (a radioactive tracer that binds to CD8+ T cells)
What this could lead to
If successful, this could provide a new way to see where immune cells are active in the brain, helping researchers understand MS and PML better.
What could go wrong
This is a very small, early-phase pilot study with only 15 participants. The tracer may not work as expected, and results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••